MedTrace Logo

A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine

NCT01103050 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-02-23

No results posted yet for this study

Summary

This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic inflammation. The study will investigate the paradigm of multiple receptor antagonism in allergic disease by combining QAV680 with a second generation H1 histamine receptor antagonist to assess possible additive or synergistic anti-allergic effects of the two compound classes.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

QAV680 + Cetirizine Placebo

DRUG

QAV680 + Cetirizine

DRUG

Cetirizine + QAV680 Placebo

DRUG

QAV680 Placebo + Cetirizine Placebo

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-22
Primary Completion
2010-07-28
Completion
2010-07-28

Countries

  • Canada

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103050 on ClinicalTrials.gov